232 related articles for article (PubMed ID: 17034670)
1. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations.
Rubenstein EB; Slusher BS; Rojas C; Navari RM
Cancer J; 2006; 12(5):341-7. PubMed ID: 17034670
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
3. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C; Slusher BS
Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
[TBL] [Abstract][Full Text] [Related]
6. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
7. A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
Sugimori Y; Ota T; Ujihira T; Ishiguro T; Ogishima D
J Obstet Gynaecol Res; 2017 Sep; 43(9):1454-1459. PubMed ID: 28952201
[TBL] [Abstract][Full Text] [Related]
8. A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting.
Yang Y; Zhang L
Chin Clin Oncol; 2020 Apr; 9(2):17. PubMed ID: 31865713
[TBL] [Abstract][Full Text] [Related]
9. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.
Rojas C; Li Y; Zhang J; Stathis M; Alt J; Thomas AG; Cantoreggi S; Sebastiani S; Pietra C; Slusher BS
J Pharmacol Exp Ther; 2010 Nov; 335(2):362-8. PubMed ID: 20724484
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for chemotherapy-induced emesis.
Navari RM; Province PS
Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
[TBL] [Abstract][Full Text] [Related]
11. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
Schwartzberg LS
Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
[TBL] [Abstract][Full Text] [Related]
13. Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
Tan M
Expert Opin Pharmacother; 2003 Sep; 4(9):1563-71. PubMed ID: 12943486
[TBL] [Abstract][Full Text] [Related]
14. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
15. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.
Navari RM
Drugs; 2013 Mar; 73(3):249-62. PubMed ID: 23404093
[TBL] [Abstract][Full Text] [Related]
16. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
Oo TH; Hesketh PJ
Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
Rojas C; Raje M; Tsukamoto T; Slusher BS
Eur J Pharmacol; 2014 Jan; 722():26-37. PubMed ID: 24184669
[TBL] [Abstract][Full Text] [Related]
18. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Billio A; Morello E; Clarke MJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
[TBL] [Abstract][Full Text] [Related]
19. Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?
Doggrell SA
Expert Opin Pharmacother; 2017 Jul; 18(10):1019-1026. PubMed ID: 28612633
[TBL] [Abstract][Full Text] [Related]
20. Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development.
Rizk AN; Hesketh PJ
Drugs R D; 1999 Oct; 2(4):229-35. PubMed ID: 10659396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
